🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,061 results for “Bio” Clear

  1. ABI-4334 Tablet

    ASSEMBLY BIOSCIENCES, INC.

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  2. ABI-5366

    ASSEMBLY BIOSCIENCES, INC.

    Recurrent Genital Herpes Simplex Type 2

    phase 1 small molecule completed

    1 trial

  3. ABI-6250

    ASSEMBLY BIOSCIENCES, INC.

    Hepatitis Delta Virus

    phase 1 small molecule completed

    1 trial

  4. ABI-H2158

    ASSEMBLY BIOSCIENCES, INC.

    Chronic Hepatitis B

    phase 1 small molecule completed

    3 trials

  5. ABI-H2158 Reference Formulation

    ASSEMBLY BIOSCIENCES, INC.

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  6. ABI-H3733

    ASSEMBLY BIOSCIENCES, INC.

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  7. ABI-H3733 Liquid Oral Dosage Form

    ASSEMBLY BIOSCIENCES, INC.

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  8. ABI-M201

    ASSEMBLY BIOSCIENCES, INC.

    Ulcerative Colitis Chronic Mild

    phase 1 small molecule terminated

    1 trial

  9. ACTR T Cell Product

    Cogent Biosciences

    Solid Tumor

    phase 1 mab terminated

    1 trial

  10. ACTR087

    Cogent Biosciences

    Multiple Myeloma

    phase 1 mab terminated

    1 trial

  11. ACTR087

    Cogent Biosciences

    Lymphoma

    phase 1 mab completed

    1 trial

  12. ACTR707

    Cogent Biosciences

    Lymphoma

    phase 1 mab terminated

    1 trial

  13. AFQ056

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 1 small molecule terminated

    1 trial

  14. AG10 oral tablet

    BridgeBio Oncology Therapeutics

    Amyloid Cardiomyopathy, Transthyretin-Related

    phase 1 small molecule completed

    1 trial

  15. AIR DNase

    Protalix BioTherapeutics

    Cystic Fibrosis (CF)

    phase 1 small molecule completed

    1 trial

  16. ALKS 33-BUP

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Abuse

    phase 1 small molecule completed

    1 trial

  17. ALT-801

    Timmune Biotech

    Obesity

    phase 1 small molecule completed

    1 trial

  18. AN OPEN LABEL, TWO PERIODS, TWO SEQUENCES, CROSSOVER, RANDOMIZED MULTIPLE DOSE BIOEQUIVALENCE STUDY OF GUANFACINE 7 MG PROLONGED-RELEASE TABLETS (TEST FORMULATION) VS. EQUAL DOSE OF INTUNIV® PROLONGED-RELEASE TABLETS (REFERENCE FORMULATION) IN HEALTHY MALE VOLUNTEERS UNDER FASTING CONDITIONS

    NEURAXPHARM AUSTRALIA PTY LIMITED

    Study performed on healthy volunteers.

    phase 1 other active

    1 trial

  19. AN OPEN-LABEL, RANDOMIZED, SINGLE DOSE, TWO-STAGE CROSSOVER ADAPTIVE BIOEQUIVALENCE STUDY OF TRIAMCINOLONE ACETONIDE 40 MG/ML STERILE INJECTABLE SUSPENSION (Test product–Lisapharma S.p.A) VERSUS KENACORT® 40 MG/ML SUSPENSION (Reference product – Bristol Myers Squibb) AFTER INTRAMUSCULAR ADMINISTRATION TO HEALTHY VOLUNTEERS

    Lacuna Pharma Pty Ltd

    Intramuscular administration of triamcinolone acetonide Lisapharma (Injectable suspension of triamcinolone acetonide) is indicated for systemic corticosteroid therapy in morbid conditions such as allergic syndrome (to control severe or debilitating conditions not treatable in a conventional way), dermatoses, generalized rheumatoid arthritis and other connective tissue diseases.

    phase 1 other active

    1 trial

  20. APR002

    BRIGHT MINDS BIOSCIENCES INC.

    COVID-19

    phase 1 small molecule completed

    1 trial

  21. APTO-253

    Aptose Biosciences

    Acute Myelogenous Leukemia in Relapse

    phase 1 small molecule terminated

    1 trial

  22. ARISE with AR

    BRIGHT MINDS BIOSCIENCES INC.

    Pediatric Cancer

    phase 1 other active

    1 trial

  23. ARQ-151 cream 0.15%

    Arcutis Biotherapeutics

    Atopic Dermatitis (Eczema)

    phase 1 small molecule completed

    1 trial

  24. ARQ-151- cream 0.3%

    Arcutis Biotherapeutics

    Plaque Psoriasis

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources